ALZN Stock Analysis: Buy, Sell, or Hold?
ALZN - Alzamend Neuro, Inc. Common Stock
$1.45
0.11 (8.21%)
▲
5d:
+10.69%
30d:
+25.0%
90d:
+30.63%
HOLD
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Sep 09, 2026
Get Alerted When ALZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: ALZN is 9.0% above its trading range ($1.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: ALZN is 9.0% above its trading range ($1.33). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: ALZN is currently trading at $1.45, which is considered extended relative to its 30-day fair value range of $1.16 to $1.33.
Technical Outlook: Technically, ALZN is showing sideways momentum. The price is approaching resistance at $1.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.2% recently.
Market Sentiment: ALZN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.00 (+1624.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ALZN is showing sideways momentum. The price is approaching resistance at $1.45. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.2% recently.
Market Sentiment: ALZN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.00 (+1624.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.16 -
$1.33
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+9.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.2%)
- BULLISH: Trading 1624.1% below Wall St target ($25.00)
- CAUTION: Extended 9.0% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$1.16 -
$1.33
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.23
Resistance Level
$1.45
Current Trend
Sideways
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.56
Wall Street Target
$25.00
(+1624.1%)
Share & Embed Analysis
Last updated: August 04, 2026 6:53 PM ET
Data refreshes hourly during market hours. Next update: 7:53 PM
Data refreshes hourly during market hours. Next update: 7:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALZN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Milton C Ault III
BUY
108388 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 47 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 51 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 58 HOLD |
